Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Drugs. 2013 Feb;24(2):212-8. doi: 10.1097/CAD.0b013e32835c032f.

Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.

Author information

1
Department of Medical Oncology, National Cancer Institute--IRCCS, Aviano (PN), Italy. mberretta@cro.it

Abstract

Few data are available on the safety and efficacy of sorafenib in HIV-infected patients with unresectable hepatocellular carcinoma (HIV-u-HCC) and concomitant highly active antiretroviral therapy (HAART). Between July 2007 and October 2010, 27 consecutive HIV-u-HCC patients were treated with sorafenib and concomitant HAART within the Gruppo Italiano Cooperativo AIDS e Tumori (GICAT). Three patients achieved a partial response, 12 achieved a stable disease, and 12 showed progression. The median time to progression and overall survival was 5.1 (range 0.5-13.3) and 12.8 (range 1.1-23.5) months, respectively. Grades 3-4 toxicities included diarrhea (four patients, 14.8%), hypertension (three patients, 11%), and hand-and-foot skin reaction (four patients, 14.9%). Most drug-related side effects were low grade and manageable. This retrospective study shows favorable survival data among HIV-u-HCC patients treated with sorafenib together with a reasonable safety profile.

PMID:
23197082
DOI:
10.1097/CAD.0b013e32835c032f
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center